A Phase 3 interventional study of Sentinel Node Technique in Ovarian Neoplasms, sponsored by Instituto de Investigacion Sanitaria La Fe. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Instituto de Investigacion Sanitaria La Fe · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 268 studies in Ovarian Neoplasms with a site in Spain — 65 open to participants now, 101 under way, 25 of them phase 3. Ovarian Neoplasms · Spain.
Among the 268 studies in Ovarian Neoplasms with a site in Spain, this one is the 123rd largest by planned enrollment of the 253 interventional ones that give a count, is one of 19 that started in 2025, is one of 66 in phase 3, reaches primary completion later than 63 of the 100 other live ones, and was the 246th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →65 of the 268 studies in Ovarian Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Spain, United States, Australia and 10 more countries
Ages 18+ · Women only
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Sites in Spain, United States, Argentina and 19 more countries
Ages 18+ · Women only
Genmab · Sites in Spain, United States, Australia and 13 more countries
Ages 18+ · Women only
Boehringer Ingelheim · Sites in Spain, United States, Belgium and 3 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Spain, United States, Argentina and 27 more countries
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
268 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 102 · Phase 2 116 · Phase 3 70 · Phase 4 1
First in 1995; this study’s year is marked. 19 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 187 across the 253 interventional studies, 220 across the 13 observational. Of the 157 that completed or were terminated, 76 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
217 of 268 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigacion Sanitaria La Fe is the lead sponsor of 58 studies on the registry; 12 are open to participants now.
Instituto de Investigacion Sanitaria La Fe has 2 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
32 of the studies in Ovarian Neoplasms with a site in Spain that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
Add all 32 to your calendar (.ics) → With an account.
Among the 268 studies in Ovarian Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial investigates the sentinel lymph node (SLN) technique as a less invasive alternative to conventional lymphadenectomy in patients with early-stage ovarian cancer. The primary objective is to evaluate the effectiveness, safety, and diagnostic accuracy of the SLN approach in detecting lymphatic metastases. By assessing its negative predictive value, the study aims to determine whether the SLN technique can reliably replace systematic pelvic and paraaortic lymphadenectomy. If successful, this technique could minimize surgical morbidity, shorten hospitalization stays, and lower complication rates, ultimately improving patient outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who have signed informed consent but do not meet all inclusion criteria and none of the exclusion criteria will be considered as selection failures.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0.2 ml (27 mBq) dose of 99mTc and 0.5 ml (1.25 mg/ml) of ICG is injected subperitoneally in the dorsal or ventral side of the pelvic infundibulum stump, and 0.2 ml (27 mBq) of 99mTc and 1 ml (1.25 mg/ml) of ICG intracervically. Sentinel nodes are located using the auditory signal from the gamma probe and visually via ICG staining with an infrared light system. After 30 minutes, all identified nodes are removed. Deferred histology applies ultra-staging for negative or micrometastatic nodes.
Procedure: Sentinel Node Technique
A 0.2 ml (27 mBq) dose of 99mTc and 0.5 ml (1.25 mg/ml) of ICG is injected subperitoneally in the dorsal or ventral side of the pelvic infundibulum stump, and 0.2 ml (27 mBq) of 99mTc and 1 ml (1.25 mg/ml) of ICG intracervically. Sentinel nodes are located using the auditory signal from the gamma probe and visually via ICG staining with an infrared light system. After 30 minutes, all identified nodes are removed. Deferred histology applies ultra-staging for negative or micrometastatic nodes.
Negative predictive value of the sentinel lymph node technique.
To determine the negative predictive value of the sentinel lymph node technique for detecting lymph node metastases, using pelvic/aortic lymphadenectomy as the Gold Standard.
Time frame: Postoperative (30 days +/- 10 days)
Concordance of Sentinel Lymph Node Technique vs. Lymphadenectomy
Evaluate the degree of concordance (sensitivity, specificity, positive predictive value, and diagnostic accuracy) between the sentinel lymph node technique and pelvic/aortic lymphadenectomy (Gold Standard) for detecting lymph node metastasis.
Time frame: Postoperative (30 days +/- 10 days).
Characterize Sentinel Lymph Node Technique vs. Lymphadenectomy for Metastasis Detection
Characterize the sentinel lymph node technique for detecting lymph node metastasis using pelvic/aortic lymphadenectomy as the Gold Standard in terms of sensitivity, specificity, positive and negative predictive value, positive and negative likelihood ratios, and effectiveness.
Time frame: Intraoperative and postoperative (30 days +/- 10 days).
Sample Characterization
Characterize the sample (through collection of baseline characteristics, medical history, tumor markers, intraoperative findings, surgical procedures, and immediate admission data).
Time frame: Baseline visit and Intraoperative
Characterize Sentinel Lymph Node Technique Based On Site of Drug Injection
Characterize the sentinel lymph node technique for detecting lymph node metastasis based on the site of drug injection, using lymphadenectomy as the Gold Standard, in terms of sensitivity, specificity, positive and negative predictive value, positive and negative likelihood ratios, and effectiveness.
Time frame: Intraoperative and postoperative (30 days +/- 10 days).
Determine Sentinel Lymph Node Procedure Rate
Determine the sentinel lymph node procedure rate.
Time frame: Intraoperative and postoperative (30 days +/- 10 days).
Determine the rate of "empty" sentinel lymph node detection.
Determine the rate of "empty" sentinel lymph node detection.
Time frame: Postoperative (30 days +/- 10 days).
Determine Pelvic and/or Paraaortic Sentinel Lymph Node Detection Rate
Determine the detection rate of pelvic and/or paraaortic sentinel lymph nodes.
Time frame: Intraoperative and postoperative (30 days +/- 10 days).
Identify the anatomical location of the sentinel lymph nodes.
Identify the anatomical location of the sentinel lymph nodes.
Time frame: Intraoperative and postoperative (30 days +/- 10 days).
Determine the number of detected lymph nodes.
Determine the number of detected lymph nodes.
Time frame: Intraoperative and postoperative (30 days +/- 10 days).
Rate of overstaging with ultrastaging.
Rate of overstaging with ultrastaging.
Time frame: Postoperative (30 days +/- 10 days).
Complications related to the sentinel lymph node technique
Complications related to the sentinel lymph node technique.
Time frame: Intraoperative and postoperative (30 days +/- 10 days).
Complications related to lymphadenectomy.
Complications related to lymphadenectomy.
Time frame: Intraoperative and postoperative (30 days +/- 10 days).
Plan to share: Undecided
Started Nov 2025 (actual). Primary completion is estimated for Jun 2028, 31 months after the start.
Of 52 non-industry phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's planned 31 months is below that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigacion Sanitaria La Fe